Traders should monitor the upcoming Phase 2b trial initiation and long-term toxicology study completion as key catalysts. Positive Phase 2 data could drive significant upside given the lack of oral targeted therapies in mast cell-driven diseases.
SEPN drugs
SEPN drug pipeline →How the stock moved after the report
BULLISH VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Mar 2 $28.64entry
- T+1 · 9mo ago −1.78%α −0.87% · $28.13
- T+5 · 8mo ago +1.47%α +2.67% · $29.06
- T+20 · 8mo ago −18.65%α −10.71% · $23.30
- T+60 · 6mo ago +7.00%α −2.33% · $30.65
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Septerna announced positive Phase 1 results for SEP-631, an oral MRGPRX2 negative allosteric modulator, showing robust, dose-dependent inhibition of mast cell activation with a favorable safety profile and pharmacokinetics supporting once-daily dosing. The company plans to advance SEP-631 into a Phase 2b trial for chronic spontaneous urticaria (CSU) in the second half of 2026 and explore additional mast cell-driven indications.
Key Facts
- SEP-631 demonstrated complete inhibition of icatibant-induced skin wheal formation at doses as low as 10 mg once daily.
- The drug was well-tolerated with an adverse event profile comparable to placebo and no serious adverse events.
- Pharmacokinetic data show a half-life of ~24 hours, supporting once-daily oral dosing without food restrictions.
- Phase 2b trial in chronic spontaneous urticaria (CSU) planned for second half of 2026, pending toxicology study completion.
- Additional development planned for chronic inducible urticaria and evaluation in atopic dermatitis, interstitial cystitis, migraine, and asthma.
Financial Impact
No direct financial impact reported; clinical milestone de-risks development and supports valuation upside.
Risk Factors
- Phase 1 results in healthy volunteers may not translate to efficacy in CSU patients.
- Regulatory delays or safety signals in long-term toxicology studies could postpone Phase 2 initiation.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3246935 |
Track record
25 reports on SEPN
6 of 6 bullish or bearish reports moved the stock their way by T+5. Best: +55.96% at T+60 after the Apr 13, 2026 report. 7 of 7 went positive at some point.
Filters
- Nov 16, 2026today Insider Cluster Neutral 2/10 Entry price pending
- Nov 16, 2026today 144 Neutral 2/10 Entry price pending
- Nov 12, 20264d ago 144 Neutral 3/10 Entry $42.60 Now $42.60 −0.00% settles Nov 20
- Nov 12, 20264d ago 144 Neutral 2/10 Entry $42.60 Now $42.60 −0.00% settles Nov 20
- Nov 12, 20264d ago 144 Neutral 3/10 Entry $41.86 Now $42.60 +1.77% settles Nov 19
- Nov 9, 20267d ago Press Release Bearish 5/10 Entry $52.34 Now $42.60 +18.61% settles Nov 17
- Nov 4, 202612d ago 8-K Neutral 3/10 Entry $47.88 to $48.56 Now $42.60 −11.03% ▲ +1.42% +2.33% vs SPY
- Nov 4, 202612d ago Press Release Neutral 4/10 Entry $47.88 to $48.56 Now $42.60 −11.03% ▲ +1.42% +2.33% vs SPY
- Sep 10, 20269w ago Press Release Neutral 2/10 Entry $38.51 to $38.69 Now $42.60 +10.62% ▲ +0.47% +0.69% vs SPY
- Sep 3, 202610w ago 3 Neutral 2/10 Entry $36.75 to $39.55 Now $42.60 +15.92% ▲ +7.62% +8.83% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers